PML and rheumatoid arthritis: Phase III studies for other adalimumab biosimilar candidate molecules have been completed or are ongoing in adult patients with RA (eg, with SB5,10 FKB32711 and PF-0641029312) or plaque psoriasis (including with MYL-1401A,13 CHS-1420,14 M92315 and MSB1102216) or both (ABP 50117 18 and GP201719 20).